Crinetics Pharmaceuticals Inc

CRNX

33.670USD

-2.640-7.27%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Crinetics Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

39 / 391

Overall Ranking

137 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Crinetics Pharmaceuticals Inc Highlights

StrengthsRisks

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 91.78% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.70M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 7.70M.

Overvalued

The company’s latest PE is -6.81, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 110.25M shares, increasing 0.01% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 514.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.06.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

83.429

Target Price

+129.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Crinetics Pharmaceuticals Inc is 6.97, ranking 155 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.97

Change

0



Financials

6.90

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.95

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.47

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Crinetics Pharmaceuticals Inc is 6.47, ranking 269 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.81, which is -31.19% below the recent high of -4.68 and -140.43% above the recent low of -16.36.

Score

Industry at a Glance

Previous score

6.47

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Crinetics Pharmaceuticals Inc is 8.50, ranking 109 out of 391 in the Biotechnology & Medical Research industry. The average price target is 83.00, with a high of 108.00 and a low of 45.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Crinetics Pharmaceuticals Inc is 6.71, ranking 156 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 39.37 and the support level at 30.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.15

Change

-0.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Crinetics Pharmaceuticals Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 122.53%, representing a quarter-over-quarter decrease of 3.11%. The largest institutional shareholder is The Vanguard, holding a total of 9.11M shares, representing 8.70% of shares outstanding, with 12.24% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

12.54M

+0.91%

The Vanguard Group, Inc.

Star Investors

9.15M

-0.93%

Wellington Management Company, LLP

8.38M

+44.34%

BlackRock Institutional Trust Company, N.A.

6.65M

+2.36%

Farallon Capital Management, L.L.C.

5.77M

+2.58%

Driehaus Capital Management, LLC

6.48M

+1.27%

T. Rowe Price Associates, Inc.

Star Investors

5.20M

-5.27%

Janus Henderson Investors

3.86M

+13.15%

EcoR1 Capital, LLC

4.29M

--

Point72 Asset Management, L.P.

Star Investors

2.00M

+0.26%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Crinetics Pharmaceuticals Inc is 5.66, ranking 42 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Crinetics Pharmaceuticals Inc

CRNX

7.32 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment